Protara Therapeutics Stock Price, News & Analysis

Protara Therapeutics, Inc. (Nasdaq: TARA) is a clinical-stage biotechnology company focused on developing therapies for people with cancer and rare diseases. According to the company’s disclosures, Protara is advancing a portfolio that centers on two investigational product candidates: TARA-002, a cell-based therapy in development for non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs), and intravenous (IV) Choline Chloride, a phospholipid substrate replacement therapy in development for patients dependent on parenteral support who cannot meet their choline needs via oral or enteral routes.

Core Programs and Therapeutic Focus

Protara describes itself as a company committed to advancing transformative therapies for people with cancer and rare diseases. Its lead candidate, TARA-002, is being evaluated in NMIBC patients with carcinoma in situ (CIS) who are either unresponsive or naïve to treatment with Bacillus Calmette-Guérin (BCG), as well as in pediatric patients with lymphatic malformations. The company reports that TARA-002 is an investigational cell-based therapy with immune-stimulating properties, developed from the same master cell bank as OK-432, which has been used as a treatment for LMs in Japan.

In NMIBC, Protara is conducting the ADVANCED-2 Phase 2 open-label trial in patients with CIS (± Ta/T1) who are BCG-unresponsive or BCG-naïve. The company has reported interim data in BCG-naïve NMIBC patients, including complete response rates at six and twelve months and a favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse events in the dataset described. Protara states that it is in dialogue with the U.S. Food and Drug Administration (FDA) regarding a registrational path for TARA-002 in both BCG-unresponsive and BCG-naïve NMIBC populations.

In lymphatic malformations, Protara is running the STARBORN-1 Phase 2 single-arm, open-label trial assessing intracystic injection of TARA-002 in pediatric patients with macrocystic and mixed cystic LMs. Interim results disclosed by the company describe high rates of clinical success, defined as complete or substantial reductions in LM volume, with many patients achieving these outcomes after one or two doses. The company reports that TARA-002 has been granted Rare Pediatric Disease, Breakthrough Therapy, and Fast Track designations by the FDA for the treatment of LMs, and that TARA-002 has been selected for the FDA’s Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) Program.

TARA-002 Mechanism and Designations

According to Protara’s descriptions, TARA-002 is an investigational, genetically distinct strain of Streptococcus pyogenes that is inactivated while retaining immune-stimulating properties. It is characterized as a first-in-class TLR2/NOD2 agonist and novel immunopotentiator derived from inactivated Streptococcus pyogenes. The company explains that its mechanism of action includes activation of innate and adaptive immune pathways within the bladder wall, with production of cytokines such as tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma, IL-6, IL-10, and IL-12, and direct tumor cell killing associated with immunogenic cell death.

For lymphatic malformations, Protara notes that TARA-002 was developed from the same master cell bank as OK-432, which has been granted marketing approval by the Japanese Ministry of Health for the treatment of LMs and has been used as a standard of care in Japan. The company cites prior clinical experience with OK-432 in a large Phase 2 trial in LMs involving over 500 patients with significant clinical success, and reports that TARA-002 has received Rare Pediatric Disease, Breakthrough Therapy, and Fast Track designations from the FDA for LMs.

IV Choline Chloride Program

In addition to TARA-002, Protara is developing IV Choline Chloride, which it describes as an investigational intravenous phospholipid substrate replacement therapy for patients receiving long-term parenteral support (PS) who cannot obtain sufficient choline from oral or enteral nutrition. The company notes that choline deficiency has been observed in a high proportion of patients dependent on PS and is associated with hepatic injury and other complications. Protara states that there are currently no approved IV choline products globally and that IV Choline Chloride has been granted Orphan Drug Designation and Fast Track Designation by the FDA for prevention and/or treatment of choline deficiency in patients on long-term parenteral nutrition and as a source of choline when oral or enteral nutrition is not possible, insufficient, or contraindicated.

The company is conducting THRIVE-3 (NCT06910943), a seamless Phase 2b/3 trial designed to assess the efficacy and safety of low and high dose IV Choline Chloride in adolescent and adult patients receiving long-term PS. As described by Protara, the trial includes an 8-week Phase 2b open-label, dose-confirmation portion followed by a 24-week Phase 3 double-blinded, randomized, placebo-controlled portion, with change in plasma choline concentration from baseline as the primary endpoint.

Regulatory and Clinical Development Strategy

Protara’s public communications emphasize engagement with the FDA on clinical and regulatory pathways for its programs. For NMIBC, the company reports that the FDA has provided written feedback supporting a controlled registrational trial of TARA-002 in BCG-naïve patients using intravesical chemotherapy as a comparator and complete response rate at six months as the primary endpoint. For lymphatic malformations, Protara has indicated that it plans to provide a regulatory update on the path to registration for TARA-002 in pediatric LMs, following the receipt of Breakthrough Therapy and Fast Track designations.

For IV Choline Chloride, Protara notes that the product candidate has received Fast Track designation and Orphan Drug Designation from the FDA, and that it is being evaluated in a registrational THRIVE-3 trial in patients on long-term parenteral support. The company highlights that IV choline is recommended for patients on parenteral support by professional societies in their guidance on parenteral nutrition, while also stating that there are no approved IV choline formulations available to these patients.

Capital Markets and Listing

Protara Therapeutics, Inc. is incorporated in Delaware and its common stock, with a par value of $0.001 per share, is listed on The Nasdaq Global Market under the trading symbol TARA, as disclosed in its Form 8-K filings. The company has conducted underwritten public offerings of its common stock under an effective shelf registration statement on Form S-3, with proceeds intended to fund the clinical development of TARA-002 and other clinical programs, as well as for working capital and general corporate purposes. An 8-K filed in December 2025 describes an offering and subsequent full exercise of the underwriters’ option, with aggregate gross proceeds of approximately $86.3 million before fees and expenses.

Disease Areas Addressed

Through its programs, Protara is targeting specific disease areas described in its public statements:

• Non-muscle invasive bladder cancer (NMIBC): Cancer found in the tissue lining the inner surface of the bladder that has not invaded the bladder muscle. Protara cites NMIBC as representing a large share of bladder cancer diagnoses in the United States and is focusing on patients with carcinoma in situ (CIS), including those who are BCG-unresponsive or BCG-naïve.
• Lymphatic malformations (LMs): Rare, congenital malformations of lymphatic vessels that often present in the head and neck region and are typically diagnosed in early childhood. The company notes that LMs can cause serious complications such as airway obstruction, intralesional bleeding, impingement on critical structures, recurrent infection, and functional or cosmetic issues.
• Choline deficiency in patients on parenteral support: Protara highlights that patients receiving long-term parenteral support are unable to synthesize choline from enteral nutrition sources and that there are no available parenteral support formulations containing choline, despite professional recommendations for IV choline in this setting.

Business Model Context

Based on the information provided in its news releases and SEC filings, Protara operates as a clinical-stage biotechnology company, with value creation centered on the discovery, development and potential future commercialization or partnering of its investigational therapies. The company’s disclosures focus on clinical trial design and outcomes, regulatory designations, and capital raising activities to support ongoing development of TARA-002 and IV Choline Chloride.

FAQs

The following frequently asked questions summarize key points about Protara Therapeutics, Inc. based solely on the available information.